Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


AavantiBio activates with $107m
Sarepta Therapeutics provided $15m in a series A round for the company, which is advancing University of Florida research.
Oxford Nanopore presses $108m
Oxford Nanopore has continued its funding streak with another $108m, bringing this year's haul to more than $208m and its overall total to around $800m.
Beyond Limits lines up $133m series C
Group 42 and BP Ventures have co-led a series C round for Caltech and Nasa spinout Beyond Limits, with $113m already closed.
Neogene sends for $110m series A
Syncona, Jeito Capital and EcoR1 Capital have co-led the Netherlands Cancer Institute-founded Neogene Therapeutics' series A round.
Recursion takes $239m funding excursion
University of Utah's drug discovery technology producer has raised series D funding to increase its post-money valuation to some $1.2bn.
Climeworks stretches out for $110m close
ETH Zurich-founded carbon capture system producer Climeworks has added $35m to its latest round to fund further business growth.
Impossible Foods digs into $200m series G
The plant-based food producer boosted its valuation to $4bn and has now raised $1.5bn since being founded by Stanford faculty in 2011.
Thrive prospers with $257m round
Thrive Earlier Detection, the developer of an early cancer screening blood test invented at JHU, has raised $257m in series B funding.

Other News

Sema4 sequences $121m series C
Sema4, spun out of Icahn School of Medicine, has achieved a valuation of more than $1bn following a $121m series C round.
Praxis Precision works out $110m series C1
Co-founded by faculty from Columbia University and University of Melbourne, Praxis Precision Medicines targets CNS disorders.
Coursera enrols in $130m series F round
Seek Group returned for a series F round that boosted the Stanford faculty-founded adult education provider's valuation to $2.5bn.
CureVac cuts $176m equity deal with GSK
GlaxoSmithKline is paying $176m for a 10% stake in University of Tübingen's RNA drug developer in connection with a strategic partnership agreement.
Harbour BioMed hoards series C funding
The Zhejiang University Future Capital-backed cancer and inflammatory disease drug developer has now raised more than $260m in under two years.
Vor leaps into $110m series B
Columbia University’s Vor Biopharma has collected more capital from shareholders including Osage University Partners, Johnson & Johnson and PureTech Health.

Editor's Picks

Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Immunocore smashes European biotech records
Immunotherapy firm Immunocore, which started life at Oxford University, raises the largest biotech round in European history.
test reg